Company Overview of Xencor, Inc.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through its proprietary XmAb technology platform. The company’s lead XmAb-engineered antibodies include XmAb5871, a B-cell inhibitor, which is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor under Phase Ib clinical trial initiation to treat asthma and allergic diseases; and XmAb5574/MOR208...
111 West Lemon Avenue
Monrovia, CA 91016
Founded in 1997
Key Executives for Xencor, Inc.
Total Annual Compensation: $363.7K
Chief Medical Officer
Total Annual Compensation: $322.5K
Chief Business Officer
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2013.
Xencor, Inc. Key Developments
Xencor, Inc. Announces Executive Appointments
Sep 2 14
Xencor, Inc. announced the appointment of Debra Zack, M.D., Ph.D., vice president, clinical development and the appointment of Lloyd Rowland, senior vice president, chief compliance officer and general counsel. Dr. Zack joins Xencor with more than a decade of experience in drug development. Prior to joining Xencor, Dr. Zack was executive director, medical scientific leader at Novartis Institute for Biological Research. Before that, she had a long career at Amgen in various pre-clinical, clinical development, and medical affairs roles, most recently as the executive director, global development lead for Enbrel and executive director, global product area lead for rheumatology and dermatology.
Xencor, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014
Jul 31 14
Xencor, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, revenues were $0.8 million against $3.9 million last year. Loss from operations was $5.1 million against $1.0 million last year. Net loss
attributable to common stockholders was $5.0 million or $0.16 per basic and diluted share against net income attributable to common stockholders of $97.0 million or $3.88 per diluted share last year.
For the six months, revenues were $3.0 million against $5.3 million last year. Loss from operations was $8.8 million against $5 million last year. Net loss attributable to common stockholders was $8.8 million or $0.28 per basic and diluted share against net income attributable to common stockholders of $92.4 million or loss of $4.35 per diluted share last year. The reduction in revenue for the three and six months ended June 30, 2014 compared to the same periods in 2013 relates primarily to the $3.0 million in milestone revenue received under the company's Morphosys collaboration in the second quarter of 2013. Revenues are earned from technology licensing fees and milestone payments from Xencor's partners for the license of its drug candidates and use of its proprietary XmAb antibody engineering technologies. The lower loss on a per share basis in the three and six month periods ended June 30, 2014 compared to the same periods in 2013 are primarily due to a non-cash expense of $48.6 million related to the loss on the settlement of convertible notes that is reflected in the 2013 losses and the additional shares reflected in the 2014 per share calculations as a result of the company's IPO in December 2013.
Xencor, Inc. to Report Q2, 2014 Results on Jul 31, 2014
Jul 24 14
Xencor, Inc. announced that they will report Q2, 2014 results After-Market on Jul 31, 2014
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|